- With the new cobas EBV and cobas BKV Tests on the cobas 6800/8800 Systems, healthcare professionals can now determine which transplant patients are at risk of further complications caused by ...

New Breakthrough Device test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus Basel, 8 September 2020 - ...

Roche (RHHBY) announced that its cobas 6800/8800 systems – two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which ...

PLEASANTON, Calif., May 23, 2019 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) 510(k) clearance for the cobas® TV/MG test for use on the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for the cobas® HIV-1 viral load test by the United States Food and Drug Administration (FDA) for use on the cobas® ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved Roche’s cobas MPX test for use on ...

Roche announced US Food and Drug Administration (FDA) 510k clearance for the cobas BKV Test on the cobas 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation ...

Accurate monitoring of Epstein-Barr virus DNA levels is critical, as they are associated with a range of life threatening-diseases including cancer in transplant patients Test meets World Health ...

The new cobas ® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems.

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.